Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (44)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Petersen, P. M.
Right arrow Articles by Skakkebæk, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petersen, P. M.
Right arrow Articles by Skakkebæk, N. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:355-358, 1994
© 1994 European Society for Medical Oncology

research-article

Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer

P. M. Petersen1,, S. W. Hansen1, A. Giwercman2, M. Rørth1 and N. E. Skakkebæk2

1University Department of Oncology, Rigshospitalet Copenhagen, Denmark
2University Department of Growth and Reproduction, Rigshospitalet Copenhagen, Denmark

Correspondence to: Peter Meidahl Petersen, M.D., Department of Oncology, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark

BACKGROUND:: The enormous differences in semen quality following cisplatin-based combination chemotherapy reported in previous studies may be caused by differences in the cisplatin dosages.

PATIENTS AND METHODS:: We examined thirty-three patients treated with conventional-dose PEB (cisplatin 20 mg/m2 x 5, q3w, etoposide 100 mg/m2 x 5 q3w and bleomycin 15 mg/m2 q1w) and 21 patients treated with high-dose PEB (cisplatin 40 mg/m2 x 5 q3w, etoposide 200 mg/m2 x 5 q3w and bleomycin 15 mg/m2 qlw).

RESULTS:: The sperm density was significantly higher (median 5.83 mill/ml) in the conventionally-treated group than in the group of high-dose-treated patients (median 0.005 mill/ml) (p = 0.008). Azoospermia was present in 19% of the conventionally- and in 47% of the high-dose-treated patients. All patients treated with a cumulative cisplatin dose above 600 mg/m2 had severe oligospermia or azoospermia. Serum values of basal follicle-stimulating hormone (FSH) (median 27.2 iu/l vs. 15.2 iu/l) and stimulated FSH (median 57.7 iu/l vs. 28.4 iu/l) were significantly higher in the high-dose group than in the conventionally-treated group. No differences could be detected in basal or stimulated testosterone or in luteinizing hormone in serum.

CONCLUSION:: In patients treated with PEB for testicular cancer, we found strong evidence that the impairment of spermatogenesis is dose-dependent.

cytotoxic agents, fertility, spermatogenesis, Leydig cell function, testicular cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J AndrolHome page
L. Marcon, B. F. Hales, and B. Robaire
Reversibility of the Effects of Subchronic Exposure to the Cancer Chemotherapeutics Bleomycin, Etoposide, and Cisplatin on Spermatogenesis, Fertility, and Progeny Outcome in the Male Rat
J Androl, July 1, 2008; 29(4): 408 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. Eberhard, O. Stahl, M. Cwikiel, E. Cavallin-Stahl, Y. Giwercman, E. C. Salmonson, and A. Giwercman
Risk factors for post-treatment hypogonadism in testicular cancer patients.
Eur. J. Endocrinol., April 1, 2008; 158(4): 561 - 570.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. Gandini, P. Sgro, F. Lombardo, D. Paoli, F. Culasso, L. Toselli, P. Tsamatropoulos, and A. Lenzi
Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients
Hum. Reprod., November 1, 2006; 21(11): 2882 - 2889.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
K. Boekelheide
Mechanisms of Toxic Damage to Spermatogenesis
J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 6 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Eberhard, O. Stahl, Y. Giwercman, M. Cwikiel, E. Cavallin-Stahl, K.B. Lundin, P. Flodgren, and A. Giwercman
Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study
Hum. Reprod., June 1, 2004; 19(6): 1418 - 1425.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Strumberg, S. Brugge, M. W. Korn, S. Koeppen, J. Ranft, G. Scheiber, C. Reiners, C. Mockel, S. Seeber, and M. E. Scheulen
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer
Ann. Onc., February 20, 2002; 13(2): 229 - 236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. N. Damani, V. Masters, M. V. Meng, C. Burgess, P. Turek, and R. D. Oates
Postchemotherapy Ejaculatory Azoospermia: Fatherhood With Sperm From Testis Tissue With Intracytoplasmic Sperm Injection
J. Clin. Oncol., February 15, 2002; 20(4): 930 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Ghosh, O. J. D’Cruz, R. K. Narla, and F. M. Uckun
Apoptosis-inducing Vanadocene Compounds against Human Testicular Cancer
Clin. Cancer Res., April 1, 2000; 6(4): 1536 - 1545.
[Abstract] [Full Text]

Home page
 JCOHome page
C. J. Sweeney, B. P. Hermans, D. K. Heilman, R. S. Foster, J. P. Donohue, and L. H. Einhorn
Results and Outcome of Retroperitoneal Lymph Node Dissection for Clinical Stage I Embryonal Carcinoma-Predominant Testis Cancer
J. Clin. Oncol., January 14, 2000; 18(2): 358 - 358.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel
The Endocrine Effects of Nonhormonal Antineoplastic Therapy
Endocr. Rev., April 1, 1998; 19(2): 144 - 172.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.